Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro

Br J Clin Pharmacol. 1989 Oct;28(4):482-7. doi: 10.1111/j.1365-2125.1989.tb03530.x.

Abstract

The formation of cytotoxic metabolites from the anticonvulsants phenytoin and carbamazepine was investigated in vitro using a hepatic microsomal enzyme system and human mononuclear leucocytes as target cells. Both drugs were metabolised to cytotoxic products. In order to assess the structural requirements for this bioactivation, a series of structurally related compounds was investigated. It was found that molecules which contain either an amide function or an aryl ring may undergo activation in vitro, but only the metabolism-dependent toxicity of the latter is potentiated by pre-treatment of the target cells with an epoxide hydrolase inhibitor. Taken collectively, these data are consistent with the concept that reactive epoxide metabolites of both phenytoin and carbamazepine may produce toxicity in individuals with an inherited deficiency in epoxide hydrolase.

MeSH terms

  • Animals
  • Anticonvulsants / pharmacokinetics*
  • Anticonvulsants / pharmacology
  • Biotransformation
  • Carbamazepine / pharmacokinetics
  • Carbamazepine / pharmacology
  • Cell Survival / drug effects*
  • Cytochrome P-450 Enzyme System / metabolism
  • Humans
  • In Vitro Techniques
  • Leukocytes / metabolism
  • Male
  • Mice
  • Mice, Inbred CBA
  • Microsomes, Liver / metabolism
  • Phenytoin / pharmacokinetics
  • Phenytoin / pharmacology
  • Urea / metabolism

Substances

  • Anticonvulsants
  • Carbamazepine
  • Phenytoin
  • Urea
  • Cytochrome P-450 Enzyme System